These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 21522099)

  • 1. Contrast induced nephropathy in patients with pre-existing renal impairment undergoing coronary angiogram and percutaneous transluminal coronary angioplasty.
    Subedi B; Siddique MA; Zaman SM; Hasan MI; Arzu J; Awal A; Fatema K
    Mymensingh Med J; 2011 Apr; 20(2):270-4. PubMed ID: 21522099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency and risk factors of contrast-induced nephropathy after cardiac catheterization in type II diabetic patients: a study among Egyptian patients.
    Sany D; Refaat H; Elshahawy Y; Mohab A; Ezzat H
    Ren Fail; 2014 Mar; 36(2):191-7. PubMed ID: 24138570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preventive effects of anisodamine against contrast-induced nephropathy in type 2 diabetics with renal insufficiency undergoing coronary angiography or angioplasty.
    Geng W; Fu XH; Gu XS; Wang YB; Wang XC; Li W; Jiang YF; Hao GZ; Fan WZ; Xue L
    Chin Med J (Engl); 2012 Oct; 125(19):3368-72. PubMed ID: 23044290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contrast induced nephropathy in diabetic and non-diabetic patients during coronary angiogram and angioplasty.
    Rahman MM; Haque HS; Banerjee SK; Ahsan SA; Rahman MF; Mahmood M; Salman M; Azam MG
    Mymensingh Med J; 2010 Jul; 19(3):372-6. PubMed ID: 20639829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk scoring system for prediction of contrast-induced nephropathy in patients with pre-existing renal impairment undergoing percutaneous coronary intervention.
    Chong E; Shen L; Poh KK; Tan HC
    Singapore Med J; 2012 Mar; 53(3):164-9. PubMed ID: 22434288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of hydration with or without n-acetylcysteine on contrast induced nephropathy in patients undergoing coronary angiography and percutaneous coronary intervention.
    Awal A; Ahsan SA; Siddique MA; Banerjee S; Hasan MI; Zaman SM; Arzu J; Subedi B
    Mymensingh Med J; 2011 Apr; 20(2):264-9. PubMed ID: 21522098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: a prospective, multicenter, randomized study to analyze the effect of hydration and acetylcysteine.
    Chen SL; Zhang J; Yei F; Zhu Z; Liu Z; Lin S; Chu J; Yan J; Zhang R; Kwan TW
    Int J Cardiol; 2008 Jun; 126(3):407-13. PubMed ID: 17651830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of high loading dose of atorvastatin in diabetic patients with renal dysfunction undergoing elective percutaneous coronary intervention: a randomized controlled trial.
    Shehata M; Hamza M
    Cardiovasc Ther; 2015 Apr; 33(2):35-41. PubMed ID: 25677920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy] trial.
    Patti G; Ricottini E; Nusca A; Colonna G; Pasceri V; D'Ambrosio A; Montinaro A; Di Sciascio G
    Am J Cardiol; 2011 Jul; 108(1):1-7. PubMed ID: 21529740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of benazepril on contrast-induced acute kidney injury for patients with mild to moderate renal insufficiency undergoing percutaneous coronary intervention.
    Li XM; Cong HL; Li TT; He LJ; Zhou YJ
    Chin Med J (Engl); 2011 Jul; 124(14):2101-6. PubMed ID: 21933609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contrast nephropathy in high-risk patients undergoing coronary angiography and intervention.
    Uddin MA; Rabbani MA; Jafary FH; Bhatti MA; Islam M
    J Coll Physicians Surg Pak; 2005 Dec; 15(12):791-4. PubMed ID: 16398973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiocontrast nephropathy: is it dose related or not?
    Mekan SF; Rabbani MA; Azhar-uddin M; Ali SS
    J Pak Med Assoc; 2004 Jul; 54(7):372-4. PubMed ID: 15449920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventive strategies of renal insufficiency in patients with diabetes undergoing intervention or arteriography (the PREVENT Trial).
    Lee SW; Kim WJ; Kim YH; Park SW; Park DW; Yun SC; Lee JY; Kang SJ; Lee CW; Lee JH; Choi SW; Seong IW; Suh J; Cho YH; Lee NH; Cheong SS; Yoo SY; Lee BK; Lee SG; Hyon MS; Shin WY; Lee SW; Jang JS; Park SJ
    Am J Cardiol; 2011 May; 107(10):1447-52. PubMed ID: 21420063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease.
    Toso A; Maioli M; Leoncini M; Gallopin M; Tedeschi D; Micheletti C; Manzone C; Amato M; Bellandi F
    Am J Cardiol; 2010 Feb; 105(3):288-92. PubMed ID: 20102936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of withdrawing vs continuing renin-angiotensin blockers on incidence of acute kidney injury in patients with renal insufficiency undergoing cardiac catheterization: Results from the Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker and Contrast Induced Nephropathy in Patients Receiving Cardiac Catheterization (CAPTAIN) trial.
    Bainey KR; Rahim S; Etherington K; Rokoss ML; Natarajan MK; Velianou JL; Brons S; Mehta SR;
    Am Heart J; 2015 Jul; 170(1):110-6. PubMed ID: 26093871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Contrast nephropathy in cardiac procedures: no advantages with prophylactic use of N-acetylcysteine (NAC)].
    Vallero A; Cesano G; Pozzato M; Garbo R; Minelli M; Quarello F; Formica M
    G Ital Nefrol; 2002; 19(5):529-33. PubMed ID: 12439841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated homocysteine and the risk of contrast-induced nephropathy: a cohort study.
    Barbieri L; Verdoia M; Schaffer A; Niccoli G; Perrone-Filardi P; Bellomo G; Marino P; Suryapranata H; Luca GD
    Angiology; 2015 Apr; 66(4):333-8. PubMed ID: 24830422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of anemia on contrast-induced nephropathy (CIN) in patients undergoing percutaneous coronary interventions.
    Li WH; Li DY; Han F; Xu TD; Zhang YB; Zhu H
    Int Urol Nephrol; 2013 Aug; 45(4):1065-70. PubMed ID: 23225080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of single-bolus administration of sodium bicarbonate to prevent contrast-induced nephropathy in patients with mild renal insufficiency undergoing an elective coronary procedure.
    Tamura A; Goto Y; Miyamoto K; Naono S; Kawano Y; Kotoku M; Watanabe T; Kadota J
    Am J Cardiol; 2009 Oct; 104(7):921-5. PubMed ID: 19766757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prevention of contrast-induced nephropathy by simultaneous hemofiltration during coronary angiographic procedures: a comparison with periprocedural hemofiltration.
    Choi MJ; Yoon JW; Han SJ; Choi HH; Song YR; Kim SG; Oh JE; Lee YK; Seo JW; Kim HJ; Noh JW; Koo JR
    Int J Cardiol; 2014 Oct; 176(3):941-5. PubMed ID: 25200848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.